Skip to content
Menu

Akari Therapeutics, Plc AKTX

Full chart Compare
Set alert

Price alert · AKTX

All alert types
6.51 USD -0.29 (-4.26%)

As ofNov 16, 2026, 1:30 PM EST

6.35 Day range 7.05
3.02 52-week range 29.32
YTD
-43.69%
1 year
-69.23%
Market cap
14.92M
Shares out
26.47M
Forward P/E
-0.29
YTD return
-43.69%
1-year return
-69.23%
50-day average
1.78
200-day average
2.41
Volume
13.14K
Avg volume
62.08K
Open
6.98
Previous close
6.80
Day's range
6.35 – 7.05
52-week range
3.02 – 29.32
Beta
0.95

5D -0.81 (-10.64%)

6.5077.50MonTueWedThuFri6.80

Key statistics

Enterprise value
35.14B
Free cash flow
-7.51M
Total cash
4.18M
Total debt
1.00M
Short % of float
0.23%

Fundamental scorecard

4 of 25 checks passed on AKTX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AKTX Revenue — quarterly 0
AKTX Net income — quarterly -4.84M
AKTX EPS — quarterly 0.00

Earnings

AKTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 6, 2024Dec 1, 20230.00———
Oct 3, 2023Jun 1, 20230.00———
Jul 19, 2023Mar 1, 20230.00———
May 15, 2023Dec 1, 20220.00———
Jan 6, 2023Sep 1, 20220.00———
Sep 27, 2022Jun 1, 20220.00-2.00——

About Akari Therapeutics, Plc

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
akaritx.com

News

Your note

Sign in to keep a note on AKTX — it syncs with the Stock Master app.

Insider holders

AKTX insider holders
InsiderRelationLatest transactionDateShares held
DICICCO WENDY FRANCESChief Financial OfficerStock Award(Grant)Apr 30, 2024158,474,000
PATEL SAMIR RASHMIKANTDirectorStock Award(Grant)Jun 27, 20243,502,890,000
PRUDO-CHLEBOSZ RAYMOND M.D.DirectorStock Award(Grant)Dec 1, 20244,916,600,000

Institution ownership

AKTX institution ownership
Holder% heldSharesValueReported
Omnia Family Wealth, LLC0.33%87,62885.88KSep 29, 2024
Citadel Advisors Llc0.13%33,26032.59KSep 29, 2024
Cerity Partners LLC0.09%23,64323.17KSep 29, 2024
Renaissance Technologies, LLC0.07%18,06917.71KSep 29, 2024
Cresset Asset Management, LLC0.07%18,40818.04KSep 29, 2024
Cornerstone Planning Group LLC 0.00%54Sep 29, 2024

Fund ownership

AKTX fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.01%1,5121.48KOct 30, 2024